ARM 210

Drug Profile

ARM 210

Alternative Names: ARM210; S48168

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARMGO Pharma
  • Developer ARMGO Pharma; Servier
  • Class Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Muscular atrophy; Spinal muscular atrophy

Most Recent Events

  • 09 Dec 2015 ARM 210 receives Rare Paediatric Disease Designation for Duchenne Muscular Dystrophy in USA
  • 09 Dec 2015 ARM 210 receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 01 Sep 2015 Phase-I clinical trials in Duchenne muscular dystrophy (In volunteers) in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top